Skip to main content

Umbrella menu

  • SfN.org
  • eNeuro
  • The Journal of Neuroscience
  • Neuronline
  • BrainFacts.org

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Latest Articles
    • Issue Archive
    • Editorials
    • Research Highlights
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • EDITORIAL BOARD
  • BLOG
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SfN.org
  • eNeuro
  • The Journal of Neuroscience
  • Neuronline
  • BrainFacts.org

User menu

  • My alerts

Search

  • Advanced search
eNeuro
  • My alerts
eNeuro

Advanced Search

Submit a Manuscript
  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Latest Articles
    • Issue Archive
    • Editorials
    • Research Highlights
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • EDITORIAL BOARD
  • BLOG
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
PreviousNext
Research ArticleNew Research, Disorders of the Nervous System

Ser46-Phosphorylated MARCKS Is a Marker of Neurite Degeneration at the Pre-aggregation Stage in PD/DLB Pathology

Kyota Fujita, Hidenori Homma, Kanoh Kondo, Masashi Ikuno, Hodaka Yamakado, Kazuhiko Tagawa, Shigeo Murayama, Ryosuke Takahashi and Hitoshi Okazawa
eNeuro 16 August 2018, 5 (4) ENEURO.0217-18.2018; DOI: https://doi.org/10.1523/ENEURO.0217-18.2018
Kyota Fujita
Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hidenori Homma
Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kanoh Kondo
Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masashi Ikuno
Department of Neurology, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-Cho, Sakyo-Ku, Kyoto, 606-8501, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Masashi Ikuno
Hodaka Yamakado
Department of Neurology, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-Cho, Sakyo-Ku, Kyoto, 606-8501, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuhiko Tagawa
Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shigeo Murayama
Department of Neuropathology, Brain Bank for Aging Research, Tokyo Metropolitan Institute of Gerontology, 35-2, Sakae-Cho, Itabashi-ku, Tokyo 173-0015, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryosuke Takahashi
Department of Neurology, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-Cho, Sakyo-Ku, Kyoto, 606-8501, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hitoshi Okazawa
Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, JapanCenter for Brain Integration Research, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Extended Data
  • Figure1
    • Download figure
    • Open in new tab
    • Download powerpoint
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Comprehensive phosphoproteomic analyses of postmortem human AD and DLB brains. A, Occipital and temporal tips of pathologically pure AD (five females) and DLB (5 females) brains along with age-matched normal controls (5 females) were used for comprehensive phosphoproteome analyses as described previously (Tagawa et al., 2015). Independent phospho-sites were compared between AD and DLB. B, Comparison of changes at four different phosphorylation sites in MARCKS [Ser27/Ser27, Ser46/Ser46, Ser145/Ser138, and Thr150/Thr143 (human/mouse)] between human DLB and AD patients. (See also Fig. 1-1.)

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Immunohistochemistry of human DLB brains. A, Costaining of pSer46-MARCKS with MAP2. Low and high magnification of temporal lobes from non-neurologic disease control patients (5 females) and human DLB patients (5 females). Images were acquired on an Olympus FV1200 IX83 confocal microscopy. All bar graphs indicate averages and SEM. In each patient, quantitative analyses of signal intensities (mean pixel intensities) were performed in 10 visual fields (100 × 100 μm) randomly selected from the corresponding area. Statistical analyses were performed with Student’s t test; **, p < 0.01. B, Staining of pSer129-α-Syn revealed multiple cytoplasmic inclusions (Lewy bodies) in the same patient group. C, Costaining of ubiquitin with pSer129-α-Syn. D, Costaining of pSer46-MARCKS with pSer129-α-Syn. E, Western blotting analysis of temporal lobes from non-DLB control patients and DLB patients with antibody against pSer46-MARCKS, total MARCKS, and β-actin. Graph shows the quantitative result of pSer46-MARCKS from 5 patients and 5 non-neurologic disease controls. The band intensity was normalized against β-actin. Statistical analyses were performed with Student’s t test; *, p < 0.05.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Chronological changes of pSer46-MARCKS in human α-Syn-BAC-Tg/GBA-hetero-KO mice. pSer46-MARCKS and pSer129-α-Syn were costained in human normal α-Syn-BAC-Tg/glucocerebrosidase (GBA)-hetero-KO mice at 1, 6, and 24 months of age (3 male mice at each time point). Images were acquired by Olympus FV1200 IX83 confocal microscopy. All bar graphs show average and SEM. Three mice were used for each group, and quantitative analyses of signal intensities (mean pixel intensities) were performed in 10 visual fields (100 × 100 μm) of each mouse, randomly selected from the brain region. Statistical analyses were performed with two-way ANOVA followed by Student’s t test; *, p < 0.05; **, p < 0.01. The increase in phosphorylation was first detected in olfactory bulb and frontal cortex, followed by the temporal and occipital cortices. Signal intensities of pSer46-MARCKS increased rapidly in the temporal and occipital regions and became most prominent among multiple brain regions. (See also Figs. 3-1, 3-2, and 3-3.)

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Costaining of pSer46-MARCKS and pSer129-α-Syn in olfactory bulb of human α-Syn-BAC-Tg/GBA-hetero-KO mice. A–C, High magnification of olfactory bulb of human α-Syn-BAC-Tg/GBA-hetero-KO mice costained with antibodies against pSer46-MARCKS and pSer129-α-Syn. Cytoplasmic staining of pSer46-MARCKS (white arrow) and dot-like stains of pSer129-α-Syn (asterisk) were detected from 1 month of age, whereas cytoplasmic aggregates of pSer129-α-Syn were detected only at 24 months. D, Ubiquitin was costained as dot-like structures or cytoplasmic aggregates in a subset of cells (yellow arrow), whereas pSer129-α-Syn–positive/ubiquitin-negative dots or aggregates were also observed.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Immunohistochemistry of the parietal lobe of α-Syn-BAC-Tg/GBA-hetero-KO mice. A, pSer46-MARCKS and pSer129-α-Syn were costained in external and internal pyramidal cell layers at 24 months of age. pSer46-MARCKS was stained in both apical dendrites and cell bodies, whereas pSer129-α-Syn was stained in cytoplasmic aggregates. B, Parietal cortex tissues from human α-Syn-BAC-Tg/GBA-hetero-KO mice were costained for pSer129-α-Syn and pSer46-MARCKS or ubiquitin at 1, 6, and 24 months of age. Costaining patterns similar to those in the olfactory bulb were confirmed in the parietal lobe.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Western blot analysis of α-Syn-BAC-Tg/GBA-hetero-KO mice at multiple time points. Left panels show Western blots of whole cortex (3 males at each time point) with antibodies against pSer46-MARCKS, pSer129-α-Syn, and ubiquitin. Right graphs show quantitative analyses of three independent blots for pSer46-MARCKS, pSer129-α-Syn, and ubiquitin; band intensities were normalized against β-actin. Statistical analyses were performed with two-way ANOVA followed by Student’s t test; *, p < 0.05; **, p < 0.01. (See also Fig. 6-1.)

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Interaction between MARCKS and α-Syn. A, Immunoprecipitates by anti-pSer46-MARCKS or anti-pSer129-α-Syn antibody from brain samples of α-Syn-BAC-Tg/GBA-hetero-KO mice at 1, 6, and 24 months were blotted with anti-pSer129-α-Syn or anti-pSer46-MARCKS antibody, respectively. B, The similar coprecipitations from temporal lobe cortexes of human DLB patients were examined.

  • Figure 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 8.

    Activation of Erk1/2 in cortical neurons of mouse PD/DLB model and human DLB patient. A, Costaining of occipital cortex tissues from α-Syn-BAC-Tg/GBA-hetero-KO (Tg) or the nontransgenic sibling control (non-Tg) mice at 1, 6, and 24 months of age, by antibodies against Erk1/2 active forms (pThr202/Tyr204-Erk1 and pThr185/Tyr187-Erk2) and against pSer46-MARCKS. Right graph shows quantitative analysis of pErk1/2 signal intensities in 3 mice (10 visual fields for mean value of each mouse). Statistical analyses were performed with two-way ANOVA followed by Student’s t test; *, p < 0.05; **, p < 0.01. B, Costaining of pSer46-MARCKS with MAP2 or GFAP in mouse cortex. C, The similar costaining of pErk1/2 and pSer46-MARCKS in human temporal lobe from DLB patients and non-neurologic disease controls. D, Western blot analyses of whole cortex tissues from α-Syn-BAC-Tg/GBA-hetero-KO (Tg) or non-Tg mice at 1, 6, and 24 months of age with anti-pErk1/2 and -Erk1/2 antibodies. E, The similar Western blot analyses of temporal lobes from human DLB patients.

Tables

  • Figures
  • Extended Data
  • Table 1.

Extended Data

  • Figures
  • Tables
  • Figure 1-1

    Detailed list of phosphorylated proteins in human AD and DLB cortex Download Figure 1-1, DOCX file.

  • Figure 3-1

    pSer46-MARCKS in human α-Syn-BAC-Tg/GBA-hetero-KO mice at 1 month of age. pSer46-MARCKS and pSer129-α-Syn were costained in human normal α-Syn-BAC-Tg/glucocerebrosidase (GBA)-hetero-KO mice at 1 month of age (3 males in each group). Signal intensities were significantly higher in yellow-marked areas. Download Figure 3-1, TIF file.

  • Figure 3-2

    pSer46-MARCKS in human α-Syn-BAC-Tg/GBA-hetero-KO mice at 6 months of age. pSer46-MARCKS and pSer129-α-Syn were costained in human normal α-Syn-BAC-Tg/glucocerebrosidase (GBA)-hetero-KO mice at 6 months of age (3 males in each group). Signal intensities were significantly higher in yellow-marked areas. Download Figure 3-2, TIF file.

  • Figure 3-3

    pSer46-MARCKS in human α-Syn-BAC-Tg/GBA-hetero-KO mice at 24 months of age. pSer46-MARCKS and pSer129-α-Syn were costained in human normal α-Syn-BAC-Tg/glucocerebrosidase (GBA)-hetero-KO mice at 24 months of age (3 males in each group). Signal intensities were significantly higher in yellow-marked areas. Download Figure 3-3, TIF file.

  • Figure 6-1

    Protein levels of pSer46-MARCKS were compared between peripheral blood cells (PBC) and whole cerebral cortex (brain) of α-Syn-BAC-Tg/GBA-hetero-KO (Tg) or the nontransgenic sibling control (non-Tg) mice at 6 months of age. Download Figure 6-1, TIF file.

Back to top

In this issue

eneuro: 5 (4)
eNeuro
Vol. 5, Issue 4
July/August 2018
  • Table of Contents
  • Index by author
Email

Thank you for sharing this eNeuro article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Ser46-Phosphorylated MARCKS Is a Marker of Neurite Degeneration at the Pre-aggregation Stage in PD/DLB Pathology
(Your Name) has forwarded a page to you from eNeuro
(Your Name) thought you would be interested in this article in eNeuro.
Print
View Full Page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Ser46-Phosphorylated MARCKS Is a Marker of Neurite Degeneration at the Pre-aggregation Stage in PD/DLB Pathology
Kyota Fujita, Hidenori Homma, Kanoh Kondo, Masashi Ikuno, Hodaka Yamakado, Kazuhiko Tagawa, Shigeo Murayama, Ryosuke Takahashi, Hitoshi Okazawa
eNeuro 16 August 2018, 5 (4) ENEURO.0217-18.2018; DOI: 10.1523/ENEURO.0217-18.2018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Ser46-Phosphorylated MARCKS Is a Marker of Neurite Degeneration at the Pre-aggregation Stage in PD/DLB Pathology
Kyota Fujita, Hidenori Homma, Kanoh Kondo, Masashi Ikuno, Hodaka Yamakado, Kazuhiko Tagawa, Shigeo Murayama, Ryosuke Takahashi, Hitoshi Okazawa
eNeuro 16 August 2018, 5 (4) ENEURO.0217-18.2018; DOI: 10.1523/ENEURO.0217-18.2018
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • Significance Statement
    • Introduction
    • Materials and methods
    • Immunohistochemistry
    • Immunoprecipitation
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
    • Synthesis
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • biomarker
  • degeneration
  • MARCKS
  • neurite
  • phosphorylation

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

New Research

  • Visual modulation of resting state alpha oscillations
  • Optimized but Not Maximized Cue Integration for 3D Visual Perception
  • Probing proteostatic stress in degenerating photoreceptors using two complementary in vivo reporters of proteasomal activity
Show more New Research

Disorders of the Nervous System

  • Mega-Analysis of Gene Expression in Mouse Models of Alzheimer’s Disease
  • Abnormal Photic Entrainment to Phase-Delaying Stimuli in the R6/2 Mouse Model of Huntington's Disease, despite Retinal Responsiveness to Light
  • MicroRNA-137 Drives Epigenetic Reprogramming in the Adult Amygdala and Behavioral Changes after Adolescent Alcohol Exposure
Show more Disorders of the Nervous System

Subjects

  • Disorders of the Nervous System
  • Home
  • Blog
  • Alerts
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Articles

  • Early Release
  • Latest Articles
  • Issue Archive
  • Video Archive
  • Editorials

For Authors

  • Information for Authors
  • Contact Information

About

  • Overview
  • Editorial Board
  • Advertise
  • For the Media
  • Privacy Policy
  • Contact Us
  • Feedback
(eNeuro logo)
(SfN logo)

Copyright © 2019 by the Society for Neuroscience.
eNeuro eISSN: 2373-2822

The ideas and opinions expressed in eNeuro do not necessarily reflect those of SfN or the eNeuro Editorial Board. Publication of an advertisement or other product mention in eNeuro should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in eNeuro.